This article is more than 5 years old. Information may no longer be current.

Partnership to provide more than $1 million for research to ‘overcome barriers’ in IBD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American Gastroenterological Association, American College of Gastroenterology and Crohn’s & Colitis Foundation have partnered with Pfizer to offer more than $1 million for research to promote health maintenance and address vaccine use in patients with inflammatory bowel disease, according to a press release.

“Applicants were encouraged to design programs or initiatives that explore or address gaps in vaccine utilization and/or communication amongst providers related to the [request for proposal] topic,” Francis A. Farraye, MD, MSc, FACG, AGAF, director of the Inflammatory Bowel Disease Center at Boston Medical Center and chair of the steering committee for the partnership between ACG, AGA, and the Crohn’s & Colitis Foundation, said in the release. “These projects were selected for their potential to overcome barriers by helping to identify and establish best practices around improving vaccine utilization and preventive health maintenance for patients with IBD. The selected projects also have the potential to be easily replicated, broadly disseminated, and widely adopted within the IBD community.”

One of the projects will seek to better understand barriers to the use of preventive health measures, such as vaccinations, among patients with IBD. The research team will look to develop web-based interventions, including an interactive website with animated video content to try to overcome those barriers. Influenza vaccine uptake will serve as the primary endpoint, according to the release.

Additionally, one of the other projects, according to the release, will seek to develop and validate the use of a patient-centered digital medicine tool to try to improve vaccination rates and preventive health compliance among patients with IBD patients.

The aim of this project, according to the release, is to create a digital vaccination module for patients and content for provider workshops that can serve as a freely available national resource for IBD centers, IBD practitioners, national organizations and patients.

Disclosure: The accepted projects will receive funding through Pfizer Global Medical Grants.